BioCept CEO to Speak in “Clinical Testing Applications of Liquid Biopsy” Section of Personalized Medicine World Conference 2016 (PMWC 2016) Today in Silicon Valley

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall will speak at today's "Clinical Testing Applications of Liquid Biopsy" session, January 25, at the Personalized Medicine World Conference (PMWC) 2016. The conference is being held in Mountain View, California. "We are happy to participate in this important conference that brings together experts from diverse fields to discuss innovations aimed at advancing personalized medicine," said Mr. Nall. "I am proud of Biocept's role in providing assays that use a simple blood draw to profile and monitor multiple types of cancers. Our tests provide actionable information that can assist physicians with personalizing treatments for their patients with cancer in order to improve outcomes." The Personalized Medicine World Conference (PMWC), in its 10th year, is an independent conference that attracts recognized authorities and experts across healthcare and biotechnology sectors. The conference showcases practical content that helps close the knowledge gaps between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic. PMWC 2016 is expected to bring together nearly 1,100 key opinion leaders and stakeholders in the personalized medicine field. Biocept, Inc., is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer.
Login Or Register To Read Full Story